BioNTech SE (BNTX) – Multi-technology Innovation

BioNTech SE (BNTX) (Q2FY23)

Stock Performance – BioNTech stock price showed a volatile trend in the past 3- months. It gave 4.88% returns during the period. The price declined by 28.39% in past 1-year. The stock has a 52-week high of €178 and its 52-week low is €88.02. In the past 3 years, the stock has given returns of ~33%. BNTX has a 50-day moving Avg. and 200-day moving Avg. of €104.35 and €111.13, respectively.

Revenue Performance – BNTX revenues reported were €167.7mn for the three months ended June 30, 2023, compared to €3,196.5mn for the comparative prior year period. For the six months ended June 30, 2023, total revenues were €1,444.7mn, compared to €9,571.1mn for the comparative prior year period.

Company Guidance for FY23 – Estimated BioNTech COVID-19 vaccine revenues for the full 2023 financial year was ~ €5bn. The company expects R&D expenses of €2,000m – €2,200m, SG&A expenses of €600m – €700m, and Capital expenditures for operating activities of €350m – €450m.

Highlights

The company is committed to revolutionizing the field of biotechnology through the implementation of a multi-technology innovation engine. This engine is fueled by a
diverse range of cutting-edge technologies, all underpinned by a profound understanding of biological principles.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10-Year Historical Performance
– Ratio Analysis
– Segment Performance
– Key Developments

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 28

To download the previous quarter’s equity/report CLICK HERE

To Download other equity/reports CLICK HERE

Follow our LinkedIn page for more updates.